Salute e Benessere
Chime Biologics Partners Polpharma Biologics to Advance Global Biosimilar Development
Polpharma Biologics, a major player in the global biosimilar market and the largest biotechnology company in Poland , brings a robust pipeline that includes multiple early-stage and late-stage biosimilars, along with two FDA/EMA-approved biosimilar products.
With an extensive track record in delivering biosimilars for global markets, Chime Biologics is well-positioned to meet the growing global demand for biosimilars. Through Chime's true end-to-end offerings, from our state-of-the-art cell line, process and analytical development capabilities, expanding manufacturing capabilities and regulatory support activities, Chime Biologics offers clients fast-tracked CMC development to commercial supply to ensure fast market entry for our clients.
"We are thrilled to contribute to Polpharma Biologics' growth as we provide all-in-one solutions to accelerate biosimilar development and reduce the time-to-market," said . "This collaboration reinforces our strategy of delivering high-quality, affordable biologics to patients worldwide."
"Partnering with Chime Biologics supports our strategic vision to swiftly bring affordable biosimilars developed in
Europe to global markets," said . "By working with Chime Biologics, we can accelerate patient access to biosimilar therapies. This partnership further strengthens Polpharma Biologics' global position as a leading biosimilars developer, while leveraging Asian partners with optimized cost-benefit ratio".
Polpharma Biologics is an international biotechnology company, with integrated operations in the European Union (EU), developing and manufacturing biosimilar medicines. Polpharma Biologics develops biosimilar therapies to treat a range of conditions in major therapeutic areas. Programs at Polpharma Biologics start in cell line development and transition through technical and clinical development to commercial-scale production, preparing drugs for future commercial partnerships with global pharmaceutical organizations. Under partnerships agreements, the company manufactures two approved biosimilars from its pipeline; ranibizumab and natalizumab. With its cell line development center in The Netherlands , and two centers of development and manufacturing in Poland , Polpharma Biologics creates development opportunities for biotechnology specialists. For more information, please visit https://polpharmabiologics.com/en/.
Chime Biologics is a leading global CDMO, focused on ensuring its partners' success in delivering innovative biologics to the world. Chime Biologics is a biologics service provider, from pre-clinical support and cell line development to clinical and commercial manufacturing of DS and DP. Employing our innovative and state-of-the-art development and manufacturing capabilities and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the global biologics industry. We share a common goal to make cutting-edge biomedicines affordable and accessible to all patients globally, fulfilling our commitment to human health. For more information, please visit www.chimebiologics.com.
Logo - https://mma.prnewswire.com/media/2555109/Chime_Biologics_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/chime-biologics-partners-polpharma-biologics-to-advance-global-biosimilar-development-302430020.html